1,25-Dihydroxyvitamin D3 and Its Analog TX527 Promote a Stable Regulatory T Cell Phenotype in T Cells from Type 1 Diabetes Patients

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Van Belle, Tom L ^a   Vanherwegen, An Sofie ^a   Feyaerts, Dorien ^a   De Clercq, Pierre ^b   Verstuyf, Annemieke ^a   Korf, Hannelie ^a   Gysemans, Conny ^a   Mathieu, Chantal ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCITRIOL DERIVATIVE; CD134 ANTIGEN; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CXCR6; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; HEMOGLOBIN A1C; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 9; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; TX527; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; ALKYNE; COLECALCIFEROL; INECALCITOL;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL HOMING; CELL PROLIFERATION; CYTOKINE PRODUCTION; DIABETIC PATIENT; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; RNA ISOLATION; T LYMPHOCYTE; ULTRAVIOLET B RADIATION; CELL DIFFERENTIATION; DRUG EFFECTS; IMMUNOLOGY;

ALKYNES; CALCITRIOL; CELL DIFFERENTIATION; CHOLECALCIFEROL; DIABETES MELLITUS, TYPE 1; HUMANS; PHENOTYPE; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 84926621134     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109194     Document Type: Article

References (42)

1. Roep BO (2003) The role of T-cells in the pathogenesis of Type 1 diabetes: From cause to cure. Diabetologia 46: 305-321.
2. Van Belle TL, Coppieters KT, von Herrath MG (2011) Type 1 diabetes: Etiology, immunology, and therapeutic strategies. Physiol Rev 91: 79-118.
3. Bluestone JA, Herold K, Eisenbarth G (2010) Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464: 1293-1300.
4. Tang Q, Bluestone JA (2008) The Foxp3+ regulatory T cell: A jack of all trades, master of regulation. Nat Immunol 9: 239-244.
5. Brusko TM, Putnam AL, Bluestone JA (2008) Human regulatory T cells: Role in autoimmune disease and therapeutic opportunities. Immunol Rev 223: 371-390.
6. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, et al. (2002) Multiple immunoregulatory defects in type-1 diabetes. J Clin Invest 109: 131-140.
7. Brusko T, Wasserfall C, McGrail K, Schatz R, Viener HL, et al. (2007) No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes 56: 604-612.
8. Putnam AL, Vendrame F, Dotta F, Gottlieb PA (2005) CD4+CD25high regulatory T cells in human autoimmune diabetes. J Autoimmun 24: 55-62.
9. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, et al. (2005) Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54: 92-99.
10. Brusko TM, Wasserfall CH, Clare-Salzler MJ, Schatz DA, Atkinson MA (2005) Functional defects and the influence of age on the frequency of CD4+ CD25+ Tcells in type 1 diabetes. Diabetes 54: 1407-1414.
11. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, et al. (2004) In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 199: 1455-1465.
12. Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, et al. (2009) Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 58: 652-662.
13. McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, et al. (2011) Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 186: 3918-3926.
14. Adams JS, Hewison M (2008) Unexpected actions of vitamin D: New perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab 4: 80-90.
15. Baeke F, Van Etten E, Gysemans C, Overbergh L, Mathieu C (2008) Vitamin D signaling in immune-mediated disorders: Evolving insights and therapeutic opportunities. Mol Aspects Med 29: 376-387.
16. Takiishi T, Van Belle T, Gysemans C, Mathieu C (2013) Effects of vitamin D on antigen-specific and non-antigen-specific immune modulation: Relevance for type 1 diabetes. Pediatr Diabetes 14: 81-89.
17. Van Belle TL, Gysemans C, Mathieu C (2013) Vitamin D and diabetes: The odd couple. Trends Endocrinol Metab 24: 561-568.
18. Adorini L, Penna G (2009) Dendritic cell tolerogenicity: A key mechanism in immunomodulation by vitamin D receptor agonists. Hum Immunol 70: 345-352.
19. Adorini L, Penna G, Giarratana N, Roncari A, Amuchastegui S, et al. (2004) Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands. J Steroid Biochem Mol Biol 89-90: 437-441.
20. Veldman CM, Cantorna MT, DeLuca HF (2000) Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 374: 334-338.
21. Jeffery LE, Burke F, Mura M, Zheng Y, Qureshi OS, et al. (2009) 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 183: 5458-5467.
22. Baeke F, Korf H, Overbergh L, Verstuyf A, Thorrez L, et al. (2011) The vitamin D analog, TX527, promotes a human CD4+CD25highCD127low regulatory T cell profile and induces a migratory signature specific for homing to sites of inflammation. J Immunol 186: 132-142.
23. American Diabetes Association (2013) Standards of medical care in diabetes- 2013. Diabetes Care 36 Suppl 1: S11-66.
24. Baeke F, Korf H, Overbergh L, Van Etten E, Verstuyf A, et al. (2010) Human T lymphocytes are direct targets of 1,25-dihydroxyvitamin D3 in the immune system. J Steroid Biochem Mol Biol 121: 221-227.
25. Scotta C, Esposito M, Fazekasova H, Fanelli G, Edozie FC, et al. (2013) Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4(+)CD25(+)FOXP3(+) T regulatory cell subpopulations. Haematologica 98: 1291-1299.
26. Lee WW, Kang SW, Choi J, Lee SH, Shah K, et al. (2010) Regulating human Th17 cells via differential expression of IL-1 receptor. Blood 115: 530-540.
27. Holick MF (2009) Vitamin D status: Measurement, interpretation, and clinical application. Ann Epidemiol 19: 73-78.
28. Sigmundsdottir H, Pan J, Debes GF, Alt C, Habtezion A, et al. (2007) DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat Immunol 8: 285-293.
29. Croft M (2010) Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 28: 57-78.
30. Ohkura N, Kitagawa Y, Sakaguchi S (2013) Development and maintenance of regulatory T cells. Immunity 38: 414-423.
31. Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, et al. (2008) The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol 181: 7350-7355.
32. Lawson JM, Tremble J, Dayan C, Beyan H, Leslie RD, et al. (2008) Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin Exp Immunol 154: 353-359.
33. Overbergh L, Decallonne B, Valckx D, Verstuyf A, Depovere J, et al. (2000) Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin Exp Immunol 120: 139-146.
34. Tang J, Zhou R, Luger D, Zhu W, Silver PB, et al. (2009) Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol 182: 4624-4632.
35. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, et al. (2001) 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 167: 4974-4980.
36. Staeva-Vieira TP, Freedman LP (2002) 1,25-dihydroxyvitamin D3 inhibits IFNgamma and IL-4 levels during in vitro polarization of primary murine CD4+ T cells. J Immunol 168: 1181-1189.
37. Correale J, Ysrraelit MC, Gaitan MI (2009) Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain 132: 1146-1160.
38. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, et al. (2007) Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 19: 345-354.
39. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, et al. (2009) Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30: 899-911.
40. Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, et al. (2002) In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)-and Th2-inducing cytokines. J Exp Med 195: 603-616.
41. Spach KM, Nashold FE, Dittel BN, Hayes CE (2006) IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol 177: 6030-6037.
42. Janson PC, Winerdal ME, Marits P, Thorn M, Ohlsson R, et al. (2008) FOXP3 promoter demethylation reveals the committed Treg population in humans. PLoS One 3: E1612.